ГОСТ ISO 10993-16—2011
[10]Katzper M. The uze of visual programming for
pharmacokinetic and harmacodynamic simulation. Centre
for Drug Evaluation and Research, FDA, 5600 Fishers
Lane, Rockville MD 20857
[11]Lin C.S., Shoaf S.E. and Griffiths J.C. Pharmacokinetic
data in the evaluation of the safety of food and colour
additives. Reg. Toxicol. Pharmacol. 15: 62—72, 1992
[12]Monro A.M. Interspecies comparisons in toxicology: The
utility and futility of plasma concentrations of the test
substance. Reg. Toxicol. Pharmacol. 12: 137—160, 1990
[13]Organization for Economic Cooperation and Development
(OECD). Guidelines for testing of chemicals — No 417
Toxicokinetics. OECD Publications
[14]Reitz R. Distribution, Persistence and elimination of toxic
agents. In: Progress in Predictive Toxicology. Clayson D
В et al. (eds.), Elsevier, New York, 1990
[15]Rowland M. and Tozer T.N. Clinical pharmacokinetics:
concepts and applications (2ndedition). Lea and Febiger,
Philadelphia, 1989
[16]Smith D.A., Humphrey M.J. and Charuel C. Design of
toxicokinetic studies. Xenobiotica 20: 1187—1199, 1990
[17]Speid L.H., Lumley C.E. and Walker S.R. Harmonisation
of guidelines for toxicity testing of pharmaceuticals by
1992. Reg. Toxicol. Pharmacol. 12: 179 — 211, 1990
[18]Travis C.B. Pharmacokinetics. In: Carcinogen Risk
Analysis. Travis C.B. (ed) Contemporary issues in risk
analysis, vol. 3, Plenum Press, New York. 1988
[19]Wagner J.G. Pharmacokinetics for pharmaceutical
scientists. Technomic publishing Co. Inc., Lancaster, 1994
[20]Wartak J. Clinical Pharmacokinetics, A modern approach
to individualised drug therapy. Clinical Pharmacology and
Therapeutics Series, Vol. 2. Praeger Publishers CBS
Educational and Professional Publishing, 1983
14